A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
- For the Study Group of Preoperative therapy for Pancreatic cancer (PREP)
Research output: Contribution to journal › Article › peer-review
94
Link opens in a new tab
Citations
(Scopus)